563 related articles for article (PubMed ID: 34368938)
1. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Dolph M; Tremblay G; Leong H
Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
[TBL] [Abstract][Full Text] [Related]
2. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Mateos MV; Gavriatopoulou M; Facon T; Auner HW; Leleu X; Hájek R; Dimopoulos MA; Delimpasi S; Simonova M; Špička I; Pour L; Kriachok I; Pylypenko H; Doronin V; Usenko G; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros AZ; Anderson LD; Bahlis NJ; Cavo M; Chai Y; Jeha J; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
J Hematol Oncol; 2021 Apr; 14(1):59. PubMed ID: 33849608
[TBL] [Abstract][Full Text] [Related]
3. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Richard S; Chari A; Delimpasi S; Simonova M; Spicka I; Pour L; Kriachok I; Dimopoulos MA; Pylypenko H; Auner HW; Leleu X; Usenko G; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros A; Anderson LD; Bahlis NJ; Facon T; Mateos MV; Cavo M; Chang H; Landesman Y; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Grosicki S; Richardson PG
Am J Hematol; 2021 Sep; 96(9):1120-1130. PubMed ID: 34062004
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Patel KK; Parker T; Di M; Bar N; Huntington SF; Giri S
Leuk Lymphoma; 2021 Nov; 62(11):2777-2784. PubMed ID: 34151696
[TBL] [Abstract][Full Text] [Related]
5. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Auner HW; Gavriatopoulou M; Delimpasi S; Simonova M; Spicka I; Pour L; Dimopoulos MA; Kriachok I; Pylypenko H; Leleu X; Doronin V; Usenko G; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros A; Anderson LD; Bahlis NJ; Facon T; Mateos MV; Cavo M; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
Am J Hematol; 2021 Jun; 96(6):708-718. PubMed ID: 33755235
[TBL] [Abstract][Full Text] [Related]
6. Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma.
Dolph M; Tremblay G; Gilligan AM; Leong H
J Health Econ Outcomes Res; 2021; 8(2):26-35. PubMed ID: 34616855
[No Abstract] [Full Text] [Related]
7. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S; Simonova M; Spicka I; Pour L; Kriachok I; Gavriatopoulou M; Pylypenko H; Auner HW; Leleu X; Doronin V; Usenko G; Bahlis NJ; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Gironella M; Jurczyszyn A; Robak P; Galli M; Wallington-Beddoe C; Radinoff A; Salogub G; Stevens DA; Basu S; Liberati AM; Quach H; Goranova-Marinova VS; Bila J; Katodritou E; Oliynyk H; Korenkova S; Kumar J; Jagannath S; Moreau P; Levy M; White D; Gatt ME; Facon T; Mateos MV; Cavo M; Reece D; Anderson LD; Saint-Martin JR; Jeha J; Joshi AA; Chai Y; Li L; Peddagali V; Arazy M; Shah J; Shacham S; Kauffman MG; Dimopoulos MA; Richardson PG; Delimpasi S
Lancet; 2020 Nov; 396(10262):1563-1573. PubMed ID: 33189178
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
10. Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.
Syed YY
Target Oncol; 2023 Mar; 18(2):303-310. PubMed ID: 36622630
[TBL] [Abstract][Full Text] [Related]
11. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
Jakubowiak AJ; Houisse I; Májer I; Benedict Á; Campioni M; Panjabi S; Ailawadhi S
Expert Rev Hematol; 2017 Dec; 10(12):1107-1119. PubMed ID: 29027825
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.
Zeng X; Peng L; Peng Y; Tan C; Wan X
Clin Ther; 2020 Feb; 42(2):251-262.e5. PubMed ID: 31973936
[TBL] [Abstract][Full Text] [Related]
15. A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.
Cass M; McDonald AB; Ben-Shahar O; Landesman Y; Kashyap T
Am J Case Rep; 2022 Apr; 23():e935353. PubMed ID: 35444159
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India.
Dixit J; Malhotra P; Mehra N; Mathew A; Kumar L; Singh A; Gupta N; Krishnamurthy MN; Roy PS; Kataki AC; Gupta S; Prinja S
Appl Health Econ Health Policy; 2024 Jul; 22(4):569-582. PubMed ID: 38448720
[TBL] [Abstract][Full Text] [Related]
18. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile.
Aceituno S; Gozalbo I; Appierto M; Lizán L
Medwave; 2018 Jun; 18(3):e7220. PubMed ID: 29958267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]